Lv1
40 积分 2023-07-03 加入
Changing standards for drug approval: A longitudinal analysis of conditional marketing authorisation in the European Union
5天前
已完结
Era of surrogate endpoints and accelerated approvals: a comprehensive review on applicability, uncertainties, and challenges from regulatory, payer, and patient perspectives
6天前
已完结
Value‐Based Pricing for Drugs With Uncertain Clinical Benefits
1个月前
已完结
Accelerated approvals: Early-phase success or premature authorization?
1个月前
已完结
The trade-off between accelerated cancer drug approvals and patient preferences
2个月前
已完结
Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs
3个月前
已完结
Progress and Challenges of the New Conditional Approval Process in China: A Pooled Analysis From 2018 to 2021
4个月前
已完结
Updated Phase 1 Results of a First-in-Human Open-Label Study of Lcar-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (Bcma)
10个月前
已完结
“There is always a better way”: Managing uncertainty in decision making about new cancer drugs in Canada
10个月前
已完结
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial
10个月前
已完结
皖公网安备34019202002308
